[HTML][HTML] Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
A Palumbo, H Avet-Loiseau, S Oliva… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, L Rosinol, P Richardson…
Journal of clinical oncology, 2015•ncbi.nlm.nih.govPurpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and
reliable tool is needed to stratify patients with MM. We combined the International Staging
System (ISS) with chromosomal abnormalities (CA) detected by interphase fluorescent in
situ hybridization after CD138 plasma cell purification and serum lactate dehydrogenase
(LDH) to evaluate their prognostic value in newly diagnosed MM (NDMM).
reliable tool is needed to stratify patients with MM. We combined the International Staging
System (ISS) with chromosomal abnormalities (CA) detected by interphase fluorescent in
situ hybridization after CD138 plasma cell purification and serum lactate dehydrogenase
(LDH) to evaluate their prognostic value in newly diagnosed MM (NDMM).
Abstract
Purpose
The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. We combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization after CD138 plasma cell purification and serum lactate dehydrogenase (LDH) to evaluate their prognostic value in newly diagnosed MM (NDMM).
ncbi.nlm.nih.gov
